Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지

Population Pharmacokinetics of Midazolam in Healthy Koreans: Effect of Cytochrome P450 3A-mediated Drug-drug Interaction

건강한 한국인에서 미다졸람 집단약동학 분석: CYP3A 매개 약물상호작용 평가

  • Shin, Kwang-Hee (College of Pharmacy, Research Institute of Pharmaceutical Sciences, Kyungpook National University)
  • Received : 2016.07.18
  • Accepted : 2016.11.16
  • Published : 2016.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: Midazolam is mainly metabolized by cytochrome P450 (CYP) 3A. Inhibition or induction of CYP3A can affect the pharmacological activity of midazolam. The aims of this study were to develop a population pharmacokinetic (PK) model and evaluate the effect of CYP3A-mediated interactions among ketoconazole, rifampicin, and midazolam. Methods: Three-treatment, three-period, crossover study was conducted in 24 healthy male subjects. Each subject received 1 mg midazolam (control), 1 mg midazolam after pretreatment with 400 mg ketoconazole once daily for 4 days (CYP3A inhibition phase), and 2.5 mg midazolam after pretreatment with 600 mg rifampicin once daily for 10 days (CYP3A induction phase). The population PK analysis was performed using a nonlinear mixed effect model ($NONMEM^{(R)}$ 7.2) based on plasma midazolam concentrations. The PK model was developed, and the first-order conditional estimation with interaction was applied for the model run. A three-compartment model with first-order elimination described the PK. The influence of ketoconazole and rifampicin, CYP3A5 genotype, and demographic characteristics on PK parameters was examined. Goodness-of-fit (GOF) diagnostics and visual predictive checks, as well as bootstrap were used to evaluate the adequacy of the model fit and predictions. Results: Twenty-four subjects contributed to 900 midazolam concentrations. The final parameter estimates (% relative standard error, RSE) were as follows; clearance (CL), 31.8 L/h (6.0%); inter-compartmental clearance (Q) 2, 36.4 L/h (9.7%); Q3, 7.37 L/h (12.0%), volume of distribution (V) 1, 70.7 L (3.6%), V2, 32.9 L (8.8%); and V3, 44.4 L (6.7%). The midazolam CL decreased and increased to 32.5 and 199.9% in the inhibition and induction phases, respectively, compared to that in control phase. Conclusion: A PK model for midazolam co-treatment with ketoconazole and rifampicin was developed using data of healthy volunteers, and the subject's CYP3A status influenced the midazolam PK parameters. Therefore, a population PK model with enzyme-mediated drug interactions may be useful for quantitatively predicting PK alterations.

Keywords

References

  1. Leucuta SE and Vlase L. Pharmacokinetics and metabolic drug interactions. Curr Clin Pharmacol 2006;1(1):5-20. https://doi.org/10.2174/157488406775268183
  2. Arendt RM, Greenblatt DJ, Garland WA. Quantitation by gas chromatography of the 1- and 4-hydroxy metabolites of midazolam in human plasma. Pharmacology 1984;29(3):158-64. https://doi.org/10.1159/000138007
  3. Seo KA, Bae SK, Choi YK, et al. Metabolism of 1'- and 4-hydroxymidazolam by glucuronide conjugation is largely mediated by UDP-glucuronosyltransferases 1A4, 2B4, and 2B7. Drug Metab Dispos 2010; 38(11):2007-13. https://doi.org/10.1124/dmd.110.035295
  4. Heizmann P, Eckert M, Ziegler WH. Pharmacokinetics and bioavailability of midazolam in man. Br J Clin Pharmacol. 1983;16(suppl):43S-9S. https://doi.org/10.1111/j.1365-2125.1983.tb02270.x
  5. Hohmann N, Kocheise F, Carls A, et al. Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans. Br J Clin Pharmacol. 2015;79(2):278-85. https://doi.org/10.1111/bcp.12502
  6. Shin KH, Choi MH, Lim KS, et al. Evaluation of endogenous metabolic markers of hepatic CYP3A activity using metabolic profiling and midazolam clearance. Clin Pharmacol Ther 2013;94(5):601-9. https://doi.org/10.1038/clpt.2013.128
  7. Bonate PL, Chapter 4 Variance Models, Weighting, and Transformations, In: San Antonio, Pharmacokinetic-Pharmacodynamic Modeling and Simulation, TX USA: Springer, 2006;126-7
  8. Kim SE, Kim BH, Lee S, et al. Population pharmacokinetics of theophylline in premature Korean infants. Ther Drug Monit. 2013;35(3):338-44. https://doi.org/10.1097/FTD.0b013e3182866695
  9. Duffull SB, Wright DF, Winter HR. Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint. Br J Clin Pharmacol. 2011;71(6):807-14. https://doi.org/10.1111/j.1365-2125.2010.03891.x
  10. Zomorodi K, Donner A, Somma J, et al. Population pharmacokinetics of midazolam administered by target controlled infusion for sedation following coronary artery bypass grafting. Anesthesiology 1998; 89(6):1418-29. https://doi.org/10.1097/00000542-199812000-00020
  11. Jones RD, Chan K, Roulson CJ, et al. Pharmacokinetics of flumazenil and midazolam. Br J Anaesth 1993; 70(3):286-92. https://doi.org/10.1093/bja/70.3.286
  12. Maitre PO, Funk B, Crevoisier C, et al. Pharmacokinetics of midazolam in patients recovering from cardiac surgery. Eur J Clin Pharmacol. 1989;37(2):161-6. https://doi.org/10.1007/BF00558225